The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
LUX head and neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients.
Barbara Burtness
Consultant or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Genentech
Research Funding - Genentech
Jean Bourhis
Honoraria - Merck Serono
Jan Baptist Vermorken
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Merck
Honoraria - Amgen; Boehringer Ingelheim; Merck
Luyan Dai
No relevant relationships to disclose
Charlotte Lind
Employment or Leadership Position - Boehringer Ingelheim
Eva Ehrnrooth
Employment or Leadership Position - Boehringer Ingelheim
Ezra E. W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim